Azithromycin and amoxicillin

It can be effective in periodontitis in combination with metronidazole and is one of the first-line treatments for group A streptococcus pharyngitis. Amoxicillin is in the class of beta-lactam antibiotics.

Beta-lactams act by binding to penicillin-binding proteins that inhibit a process called transpeptidation, leading to activation of autolytic enzymes in the bacterial cell wall. This process leads to lysis of the cell wall, and thus, the destruction of the bacterial cell.

This type of activity is referred to as bactericidal killing. Amoxicillin administration can also be in combination with a beta-lactamase inhibitor. Some examples of these are clavulanic acid and sulbactam. These beta-lactamase inhibitors work by binding irreversibly to the catalytic site of an organism’s penicillinase enzyme, which causes resistance to the original beta-lactam ring.

These drugs do not have inherent bactericidal activity; however, when coupled with amoxicillin, they may broaden spectrum amoxicillin to organisms that produce the penicillinase enzyme.[3] Administration. Bactericidal antibiotics, such as amoxicillin, often are most effective in a “time-dependent” manner, rather than a “concentration-dependent” manner. Time-dependent refers to the time amoxicillin and acne that serum concentrations exceed the minimum-inhibitor-concentration for the microorganism.

Therefore, they are often dosed more frequently, rather than the concentration-dependent drugs, which can be dosed, for example, daily. The more “around-the-clock” dosing provides less variation in peak and trough serum levels. Amoxicillin is an oral antibiotic; whereas, ampicillin can be given orally, intravenously, or intramuscularly.

Amoxicillin comes in immediate-release or extended-release tablets. If given in suspension, it may be mixed and administered with formula, milk, water, fruit juice, ginger ale, or other cold drinks. Administration should take place immediately after mixing. Extended-release tablets should not be crushed, and the administration should be within 1 hour after finishing a meal.

Amoxicillin is sometimes preferred over penicillin in children because of its taste. It is important to note that it is excreted by in the majority of people by the kidney, and some renal adjustment and extra caution may be necessary for renal insufficiency.

It is reported to be partially dialyzable, and therefore, immediate-release tablets can be an option for dosing after hemodialysis.

There are no guidelines for hepatic dosing or geriatric dosing. It was a pregnancy category B drug under the old FDA classification system, which means there have been no studies demonstrating clear risk. It has also been reported to get excreted in breast milk.

Amoxicillin is well-tolerated, but some common complaints can be gastrointestinal (GI) symptoms,

such

Of note, patients who take amoxicillin may have less diarrhea than those who take ampicillin, which may lead to better absorption in the gut. Another significant complication to be aware of is hypersensitivity reactions.

Amoxicillin can lead to type-I, II, III, or IV reactions. It is important to differentiate between a type-I and type-IV hypersensitivity reaction because one may be more dangerous than the other.

A type-I reaction is an IgE-mediated hypersensitivity to a sensitized patient that triggers widespread histamine release leading to an urticarial like pruritic rash or even more severe systemic symptoms, such as anaphylaxis.

A type-IV hypersensitivity reaction does not get mediated by histamine release, and is more papular or morbilliform and often not itchy.

Professionals suggest that almost all patients that receive amoxicillin inadvertently for infectious mononucleosis develop a maculopapular rash caused by a type

IV-mediated

These types of reactions are not known to lead to anaphylaxis. Any previous anaphylactic reaction or serious skin reaction (for example, Stevens-Johnson syndrome) to amoxicillin or any other beta-lactam is a significant contraindication to amoxicillin.

These reactions may have crossover sensitivity with cephalosporins or carbapenems.

It is important to note that newer data has suggested a much lower cross-reactivity with cephalosporins and carbapenems than once suspected. Another important consideration is to determine if the patient’s allergic rash is a type-I or a type-IV hypersensitivity reaction.

Occasionally patients will report a childhood allergy to amoxicillin, which is, in fact, a type-IV-mediated hypersensitivity reaction, often in the setting of infectious mononucleosis; this is not a contraindication to giving repeat amoxicillin.

A type-1 mediated hypersensitivity reaction is, however, a contraindication given that a repeat exposure puts the patient at risk for anaphylaxis.

Skin testing has been approved to help assist in hypersensitivity to penicillins. Reports are that the risk of an allergic reaction in a patient with a positive skin test is roughly four percent, whereas a negative skin test has a relatively high sensitivity in ruling out a type-I hypersensitivity reaction.[4] Monitoring.

It is essential to be aware of hypersensitivity reactions, and the patient should understand to notify their physician of any rashes.[4] Mild diarrhea is often toleratable.[5] However, prolonged diarrhea with fever and abdominal pain should prompt evaluation by a clinician. In a patient on a short-term course of amoxicillin, no specific laboratory monitoring parameters are suggested.

During prolonged administration, such as for osteomyelitis, it is essential to monitor renal and hepatic function as well as hematologic function periodically throughout treatment.

Amoxicillin is a common antibiotic that is often prescribed by nurse practitioners, primary care providers, and internists.

The drug is very safe, but it is essential always to get a proper history of allergy before prescribing the medication.[4][6] Despite its safety record and frequency of use, amoxicillin still requires the efforts of an interprofessional healthcare team. The clinician (MD, DO, NP, PA) will initiate therapy, but a pharmacist should verify the dosing and duration are correct for the infection being treated and verify that there are no drug interactions that could impede treatment. Nursing can counsel on administration, verify compliance, reinforce along with the pharmacist to take the entire course, and not stop when they start to feel better.

Any issues the nurse or pharmacist encounters need to go to the prescriber immediately.

These examples of interprofessional team stewardship will improve the likelihood of positive patient outcomes.

To access free multiple choice questions on this topic, click here.

Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. Background: When prescribing antibiotics for common indications, clinicians need information about both harms and benefits, information that is currently available only from observational studies.

We quantified the common harms of the most frequently prescribed antibiotic, amoxicillin, from randomized placebo-controlled trials.

Methods: For this systematic review, we searched MEDLINE, Embase and the Cochrane Central Register of Controlled Trials, without language restriction, for any randomized, participant-blinded, placebo-controlled trials of amoxicillin or amoxicillin–clavulanic acid for any indication, in any setting.

Results: Of 730 studies identified, we included 45 trials: 27 involving amoxicillin, 17 involving amoxicillin–clavulanic acid and 1 involving both. The indications for antibiotic therapy were variable. The risk of bias was low, although only 25 trials provided data suitable for assessment of harms, which suggested under-reporting. Diarrhea was attributed to amoxicillin only in the form of amoxicillin–clavulanic acid (Peto odds ratio [OR] 3.30, 95% confidence interval [CI] 2.23–4.87).

The OR for candidiasis (3 trials) was significantly higher (OR 7.77, 95% CI 2.23–27.11). Rashes, nausea, itching, vomiting and abnormal results on liver function tests were not significantly increased. The results were not altered by sensitivity analyses, nor did funnel plots suggest publication bias. The number of courses of antibiotics needed to harm was 10 (95% CI 6–17) for diarrhea with amoxicillin–clavulanic acid and 27 (95% CI 24–42) for candidiasis with amoxicillin (with or without clavulanic acid). Interpretation: Diarrhea was caused by use of amoxicillin–clavulanic acid, and candidiasis was caused by both amoxicillin and amoxicillin–clavulanic acid. Harms were poorly reported in most trials, and their true incidence may have been higher than reported.

Nevertheless, these rates of common harms associated with amoxicillin therapy may inform decisions by helping clinicians to balance harms against benefits.

Most antibiotics are prescribed by primary care clinicians mixing amoxicillin for common infections, particularly acute respiratory infections. 1 However, for most acute respiratory infections, antibiotics provide only marginal benefits, and an inevitable consequence of this injudicious use is the prospect of antibiotic resistance. One way to reduce antibiotic prescribing in primary care is to explain to patients how little these drugs help for many common infections and to apply a process of shared decision-making during the consultation.

The

practice

Serious harms are probably sufficiently rare to be discounted by most clinicians and their patients.

3 Yet when the decision to use or not use antibiotics relates to a self-remitting illness, for which the benefits are likely to be modest at best, the more common, mild harms of antibiotics become important. Unfortunately, common harms from antibiotics are poorly quantified, and clinicians cannot talk to patients with confidence about their likelihood. Current understanding of the common harms of antibiotics is derived largely from observational studies. However, estimates of common harms from such studies may be biased, principally because it is difficult to distinguish adverse drug reactions from disease-related symptoms.

One approach to addressing this problem is to investigate common harms encountered in randomized controlled trials of antibiotic against placebo. This study design controls for disease-related symptoms, allowing for better quantification of antibiotic-related adverse effects. The most common antibiotic used in primary care is amoxicillin, either alone or in combination with clavulanic acid.

“Common harms” can be defined as those frequent enough to be observable in the patient samples of most randomized trials and occurring during the recording of primary outcomes in such studies (with recognition that some of the adverse effects will occur later).

Accordingly, we systematically reviewed all published placebo-controlled randomized trials of amoxicillin or amoxicillin–clavulanic acid for any indication, with the rationale that the risks of drug-induced harms are independent of the condition being treated. This systematic review with meta-analysis was registered with Prospero on May 11, 2012 (protocol available at www.crd.york.ac.uk/prospero/, registration number CRD42012002281).

We searched MEDLINE (1946 to June week 4, 2013), Embase (2010 to July 2013) and the Cochrane Central Register of Controlled Trials (to 2013, issue 7) using the Cochrane highly sensitive search strategy for randomized trials (for the full search strategy, see Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140848/-/DC1).

We considered all randomized, participant-blinded, placebo-controlled trials, in any language, with any population, in which amoxicillin or amoxicillin–clavulanic acid was used to treat any condition.

We excluded studies that involved coadministration of any drug other than acetaminophen (paracetamol). Outcomes of interest were amoxicillin and allopurinol any reported adverse event, including nausea, vomiting, diarrhea, rash, candidiasis, itch and abnormal results on liver function tests. and A.R.) independently screened the titles and abstracts of retrieved studies to identify those that appeared to meet the inclusion criteria. The full texts of these articles were similarly independently assessed for eligibility. Any disagreements were resolved by discussion, and a third author (C.D.M.) arbitrated if necessary. The two reviewers used a standardized form to independently extract data from eligible studies, including event rates (with the intention-to-treat population as the denominator) and estimates of bias. Discrepancies were resolved by discussion, and the same third

author